Status: Recruiting
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment
To prospectively evaluate the efficacy and safety of DPYD-guided dosing strategies in a real-world clinical setting, specifically by comparing the incidence of severe (Grade 3 and 4) fluoropyrimidine-related toxicities of heterozygous DPYD variant patients assigned to DPYD-guided reduced dosing versus patients with standard dosing in the control arm.
Participants needed: 100
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: Rutgers, The State University of New JerseyUpdated: Nov 13, 2025Locations: 12
Eligibility criteria
Diagnosis of cancer in either the adjuvant or metastatic setting requiring initi... [+5]
Patients for whom 5-FU or Capecitabine therapy is contraindicated or not deemed... [+2]